ACLX
Arcellx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ACLX
Arcellx, Inc.
A company that develops innovative immunotherapies for cancer
800 Bridge Parkway, Redwood City, CA 94065
--
Arcellx, Inc., was incorporated in Delaware in December 2014. They are a clinical-stage biotechnology company reimagining cell therapy by developing innovative immunotherapies for patients with cancer and other incurable diseases. Their new synthetic binding scaffold D-Domain aims to overcome the limitations of traditional chimeric antigen receptor T cells.
Company Financials
EPS
ACLX has released its 2025 Q3 earnings. EPS was reported at -0.99, versus the expected -1.03, beating expectations. The chart below visualizes how ACLX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ACLX has released its 2025 Q3 earnings report, with revenue of 4.95M, reflecting a YoY change of -80.99%, and net profit of -55.78M, showing a YoY change of -115.65%. The Sankey diagram below clearly presents ACLX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
